We evaluated ranolazine as a blocker of wild-type Nav1.7 channels and of mutant Nav1.7 channels that underlie two different neuropathic human pain disorders, IEM and PEPD, and assessed its ability to reduce excitability of DRG neurons that express WT or pain-causing mutant Nav1.7 channels. Here, SCN9A is linked to paroxysmal extreme pain disorder.